Abstract |
Eleven HBsAg chronic carriers were treated with recombinant- interferon (rIFN)-alpha-2A with either 20 X 10(6) (n = 6) or 10 X 10(6) IU/m2 body surface (n = 5), i.m. twice weekly for 6 months. HBV-markers were tested monthly for 15 months. Throughout the follow-up, 6 patients (54%) became HBeAg, HBV- DNAp and HBV- DNA negative (responders). In addition, 8 were HBcAg-negative, 10 anti-HBc- IgM-negative and 2 HBsAg/ IgM complexes negative. All patients gave polymerized human serum albumin receptors and HBsAg-positive results. The low rIFN dose seems to be more efficient for clearing HBV-markers than the high dose. Responder patients already showed lower (P less than 0.05) HBsAg concentration and HBsAg/ IgM complexes levels in their basal samples as compared to non-responders, and exhibited under rIFN treatment significant decreases (P less than 0.05) in all HBV-markers studied. In conclusion, the most reliable HBV-markers to be assayed in the evaluation of antiviral therapy are HBV- DNA, HBV- DNAp or HBcAg. The testing of pHSA-R, HBsAg/ IgM complexes and anti-HBc- IgM does not seem to be very useful.
|
Authors | I Mora, J C Porres, J Bartolomé, J A Quiroga, J Gutiez, C Hernández Guio, C Bas, V Carreño |
Journal | Journal of hepatology
(J Hepatol)
Vol. 4
Issue 1
Pg. 29-36
(Feb 1987)
ISSN: 0168-8278 [Print] Netherlands |
PMID | 3571931
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antigen-Antibody Complex
- DNA, Viral
- Hepatitis B Antibodies
- Hepatitis B Antigens
- Interferon Type I
|
Topics |
- Adolescent
- Adult
- Antigen-Antibody Complex
(isolation & purification)
- Carrier State
(immunology, microbiology, therapy)
- DNA, Viral
(isolation & purification)
- Female
- Hepatitis B
(immunology, microbiology, therapy)
- Hepatitis B Antibodies
(isolation & purification)
- Hepatitis B Antigens
(isolation & purification)
- Hepatitis B virus
(isolation & purification)
- Humans
- Interferon Type I
(administration & dosage, therapeutic use)
- Male
- Middle Aged
|